TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07593625: Evaluation Glucose Control Using a Next-Generation Automated Insulin Delivery Algorithm in Individuals With Type 1 Diabetes: EVOLUTION T1D

Sponsor: Insulet Corporation · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 80 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$16,480,000

Rescue Site Savings

+$10,866,500

Unlock Full NCT07593625 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07593625 Rescue Dossier →